Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

Scpharmaceuticals (($SCPH)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for ...

Ernst emphasized the strategic transformation of Tivic into a diversified therapeutics company, combining biologic and bioelectronic approaches to address immune dysregulation. This includes ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc.

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

The U.S. FDA approved 16 drugs in February, up from 12 in January but still falling short of the 2024 monthly average of 19 approvals. Just two of those were new molecular entities (NMEs), continuing ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...